SEARCH

SEARCH BY CITATION

References

  • 1
    Samuel D, Bismuth H. Liver transplantation for hepatitis B. Gastroenterol Clin North Am 1993; 22: 271283.
  • 2
    Benner KG, Lee RG, Keeffe EB, Lopez RR, Sasaki AW, Pinson CW. Fibros-ing cytolytic liver failure secondary to recurrent hepatitis B after liver transplantation. Gastroenterology 1990; 103: 13071312.
  • 3
    Todo S, Demetris AJ, Van Thiel D, Teperman L, Fung JJ, Sarzl TE. Orthotopic liver transplantation for patients with hepatitis B virus—related liver disease. Hepatology 1991; 13: 619626.
  • 4
    Shah G, Demetris AJ, Gavaler JS, Lewis JH, Todo S, Starzl TE, van Thiel DH. Incidence, prevalence, and clinical course of hepatitis B following liver transplantation. Gastroenterology 1992; 103: 323329.
  • 5
    Lauchert W, Müller R, Pichlmayr R. Immunoprophylaxis of hepatitis B virus reinfection in recipients of human liver allografts. Transplant Proc 1987; 19: 23872389.
  • 6
    Müller R, Gubernatis G, Farle M, Niehoff G, Klein H, Wittekind C, Tusch G, et al. Liver transplantation in Hbs antigen (HBsAg) carriers. Prevention of hepatitis B virus (HBV) recurrence by passive immunisation. J Hepatol 1991; 13: 9096.
  • 7
    Samuel D, Bismuth A, Mathieu D, Arulnaden JL, Reynes M, Benhamou JP, Brechot C, et al. Passive immunoprophylaxis after liver transplantation in HBsAg positive patients. Lancet 1991; 337: 813815.
  • 8
    Okamoto H, Tsuda F, Sakugawa H, Sastrosoewignjo RI, Imai M, Miya-kawa Y, Mayumi M., Typing hepatitis B virus by homology in nucleotide sequence: comparison of surface antigen subtypes. J Gen Virol 1988; 69: 25752583.
  • 9
    Carman WF, Thomas H, Esteban D., Viral genetic variation: hepatitis B as a clinical example. Lancet 1993; 341: 349352.
  • 10
    Milich DR, Thornton GB, Neurath A, Kent S, Michel M, Tiollais P, Chisari FV. Enhanced immunogenicity of the pre-S region of hepatitis B surface antigen. Science 1985; 228: 11951199.
  • 11
    Milich DR, McNamara MK, McLachlan A, Thornton GB, Chisari FV. Distinct H-2-linked regulation of T-cell responses to the PreS and S regions of the same hepatitis B surface antigen polypeptide allows circumvention of nonresponsiveness to the S region. Proc Natl Acad Sci USA 1985; 82: 81688172.
  • 12
    Milich DR, McLachlan A, Chisari FV, Nakamura T, Thornton GB. Two distinct but overlapping antibody binding sites in the PreS(2) region of HBsAg localized within 11 continuous residues. J Immunol 1986; 137: 27032710.
  • 13
    Milich DR, McLachlan A, Chisari FV, Kent SBH, Thornton GB., Immune response to the PreS(1) region of the hepatitis B surface antigen (HBsAg): a preS(1)-specific T cell response can bypass nonresponsiveness to the preS(2) and S regions of HBsAg. J Immunol 1986; 137: 315322.
  • 14
    Neurath AR, Kent SBH, Strick N, Parker K. Identification and chemical synthesis of a host cell receptor binding site on hepatitis B virus. Cell 1986; 46: 429436.
  • 15
    Neurath AR, Kent SBH, Parker K, Prince AM, Strick N, Brotman B, Sproul P. Antibodies to a synthetic peptide from the preS 120–145 region of the hepatitis B virus envelope are virus neutralizing. Vaccine 1986; 4: 3537.
  • 16
    Neurath AR, Strick N, Sproul P. Search for hepatitis B virus cell receptors reveals binding sites for interleukin 6 on the virus envelope protein. J Exp Med 1992; 175: 461469.
  • 17
    Lu CC, Chen M, Ou JH, Yen TSB. Key role of a CCAAT element in regulating hepatitis B virus surface protein expression. Virology 1995; 206: 11551158.
  • 18
    Gerken G, Kremsdorf D, Capel F, Dauguet C, Manns M, Meyer zum Biischenfelde K-H, Brechot C. Hepatitis B defective virus with rearrangements in the preS gene during chronic HBV-infection. Virology 1991; 183: 555565.
  • 19
    Santantonio T, Jung MC, Schneider R, Fernholz D, Milella M, Monno M, Pastore G, et al. Hepatitis B virus genomes that cannot synthesize pre-82 proteins occus frequently and as a dominant virus population in chronic carriers in Italy. Virology 1992; 188: 948952.
  • 20
    Böker KH, Ringe B, Krüger M, Pichlmayr R, Manns MP. Prostaglandin E plus famciclovir—a new concept for the treatment of severe hepatitis B after liver transplantation. Transplantation 1994; 57: 17061708.
  • 21
    Michitaka K, Durrazzo M, Tillmann HL, Walker D, Philipp T, Manns MP. Analysis of hepatitis C virus genome in patients with autoimmune hepatitis type 2. Gastroenterology 1994; 106: 16031610.
  • 22
    Tillmann HL, Trautwein C, Walker D, Kubicka S, Böker K, Manns M. Prevalence of the hepatitis B e-minus variant in northern Europe. Gut 1995; 37: 568573.
  • 23
    Kubicka S, Trautwein C, Schrem H, Tillmann H, Manns MP. Hepatocellu-lar carcinoma and P53 mutation in northern Europe. J Hepatol 1995; 23: 412419.
  • 24
    Descombes P, Chojkier M, Lichtsteiner S, Falvey E, Schibler U. LAP, a novel member of the C/EBP gene family, encodes a liver-enriched tran-scriptional activator protein. Genes Dev 1990; 4: 15411551.
  • 25
    Trautwein C, Walker D, Plümpe J, Manns MP. Transactivation of LAP/ NF-IL6 is mediated by an acidic domain in the N-terminal part of the protein. J Biol Chem 1995; 270: 1513015136.
  • 26
    Galibert F, Mandart E, Fitoussi F, Tiollais P, Charny P. Nucleotide sequence of the hepatitis B virus genome (subtype ayw) cloned in E. coli. Nature 1979; 281: 646650.
  • 27
    Valenzuela P, Quiroga M, Zalvidar J, Gray P, Rutter WJ. The nucleotide sequence of the hepatitis B viral genome and the identification of the major viral genes. In: FieldsBN, JaenischR, FoxCF, eds. Animal virus genetics: New York: Academic Press, 1980: 5770.
  • 28
    Kobayashi M, Koike K. Complete nucleotide sequence of hepatitis B virus DNA of subtype adr and its conserved gene organization. Gene 1984; 30: 227232.
  • 29
    Okamoto H, Imai M, Shimozaki M, Hoshi Y, Iizuka H, Gotanda T, Tsuda F, et al. Nucleotide sequence of a cloned hepatitis B virus genome, subtype ayr: comparison with genomes of the other three subtypes. J Gen Virol 1986; 67: 23052314.
  • 30
    Minims LT, Floreani M, Tyner J, Whitters E, Rosenlof R, Wray L, Goetze A, et al. Discrimination of hepatitis B virus (HBV) subtypes using monoclonal antibodies to the preSl and preS2 domains of the viral envelope. Virology 1990; 176: 604619.
  • 31
    Itoh Y, Takai E, Ohnuma H, Kitajima K, Tsuda F, Machida A, Mishiro S, et al. A synthetic peptide vaccine involving the product of the pre-S(2) region of hepatitis B virus DNA: protective efficacy in chimpanzees. Proc Natl Acad Sci U S A 1986; 83: 91749178.
  • 32
    Neurath AR, Thanavala Y. Hepadnaviruses. In: Van RegenmortelMHV, NeurathAR, eds. Immunochemistry of Viruses II. Amsterdam: Elsevier, 1990: 403458.
  • 33
    Petit MA, Dubanchet S, Capel F, Voet P, Dauguet C, Hauser P., HepG2 cell binding activities of different hepatitis B isolates: inhibitory effect of anti-HBs and anti-preS (21–47). Virology 1991; 180: 483491.
  • 34
    Petit MA, Strick N, Dubanchet S, Capel F, Neurath AR. Inhibitory activity of monoclonal antibody F35.25 on the interaction between hepatocytes (HepG2 cells) and preS1-specific ligands. Mol Immunol 1991; 28: 517521.
  • 35
    Heermann KH, Goldmann U, Schwartz W, Seyffarth T, Baumgarten H, Gerlich WH. Large surface proteins of hepatitis B virus containing the pre-S sequence. J Virol 1994; 52: 396402.
  • 36
    Zhou D-X, Yen TSB. The hepatitis B virus S promoter comprises a CCAAT motif and two initiation regions. J Biol Chem 1991; 266: 2341623421.
  • 37
    Kozak M., The scanning model for translation: an update. J Cell Biol 1989; 108: 229241.
  • 38
    Milich DR, Jones JE, McLachlan A, Bitter G, Moriarty A, Hughes JL. Importance of subtype in the immune response to the preS(2) region of the hepatitis B surface antigen II. Synthetic PreS(2) immunogen. J Immunol 1990; 144: 35443551.
  • 39
    Lau J, Bain VG, Davies SE, O'Grady JG, Alberti A, Alexander GJM, Williams R. High level expression of hepatitis B viral antigens in fibrosing cholestatic hepatitis. Gastroenterology 1992; 102: 956962.
  • 40
    Samuel D, Müller R, Alexander G, Fassati L, Ducot B, Benhamou J-P, Bismuth H, and The investigators of the European Concerted Action on Viral Hepatitis study. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993; 329: 18421847.
  • 41
    Indications for liver transplantation. Text of a consensus conference. Ann Gastroenterol Hepatol (Paris) 1994; 30: 101104, 109–112.
  • 42
    Grellier L, Brown D, Berenek P, Rolles K, Burroughs A, Dusheiko G. Lamivudine prophylaxis: a new strategy for prevention of hepatitis B reinfection in liver transplantation for hepatitis B DNA positive cirrhosis. Single topic symposium on liver transplantation for chronic viral hepatitis. Reston, VA, 1995.
  • 43
    Krüger M, Tillmann HL, Trautwein C, Bode U, Oldhafer K, Böker KHW, Pichlmayr R, et al. Treatment of hepatitis B virus reinfection after liver transplantation with famciclovir. Hepatology 1994; 20: 130A.
  • 44
    Carman FW, Trautwein C, van Deursen FJ, Colman K, McLntyre G, Kliem V, Waters J, et al. Hepatitis B virus envelope variation after transplantation with and without polyclonal antibody pressure. Hepatology 1994; 20: 138A.
  • 45
    Robinson WS. Hepadnaviridae and their replication. In: Fundamental virology, 2nd ed. FieldsBN, KnipeDM, eds. New York: Raven Press, 1991: 9891021.
  • 46
    Raney AK, Millich DR, McLachlan A. Characterization of hepatitis B virus major surface antigen gene transcriptional regulatory elements in differentiated hepatoma cell lines. J Virol 1989; 63: 39193925.